Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

T cell receptor-deficient T cell compositions

a technology of t cell receptors and compositions, applied in the field of t cell receptor-deficient t cell compositions, can solve the problems of limiting the potential of immune cells to become, cancer continues to grow, and patients with advanced cancer may have gone through chemotherapy rounds, etc., to reduce or improve, or prevent or treat diseases

Active Publication Date: 2015-05-12
TRUSTEES OF DARTMOUTH COLLEGE THE
View PDF9 Cites 11 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The immune cells from patients with advanced cancer, who may have gone through rounds of chemotherapy, do not respond as robustly as healthy individuals.
Moreover, cancer patients are often elderly and may suffer from other diseases that may limit the potential of their immune cells to become primed effector cells, even after in vitro activation and expansion.
Because each therapy must be custom made for the patient, this process requires weeks from the time the decision to undertake such therapy is made; meanwhile, the cancer continues to grow.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

example 1

Production of T Cell Receptor (TCR)-Deficient T Cells

[0115]Minigenes are encoded on a retrovirus expression plasmid (e.g. pFB-neo or pSFG) containing 5′ and 3′ LTR sequences. The plasmids are packaged in a retroviral packaging cell line, such as PT67 or PG13, and viral particles are collected once the packaging cells have grown to confluence. T cells are then activated by PHA, anti-CD3, or anti-CD3 / 28 mAbs for 1 to 3 days in complete medium (or serum free medium) plus rIL-2 (25 U / ml), and T cells are transduced by spinoculation at 32° C. in the presence of retronectin or polybrene. After resting for some 5 to 7 hours, the cells are washed and placed in fresh medium plus IL-2 for 2 to 7 days. Cells are counted periodically to avoid excessive cell concentration (i.e., >2×106 cells / ml) and re-plated at 7×105 cells / ml. Selection medium to remove non-transduced T cells is optionally used after 2 days for a period of 3 to 5 days. Live cells are harvested by Lymphoprep™ (Sentinel, Milan, I...

example 2

Production of T Cell Receptor (TCR)-Deficient T Cells Expressing chNKG2D

[0119]In this example, simultaneous expression of a chNKG2D receptor and inhibition of endogenous TCR expression is performed. In this example, a murine chNKG2D receptor is used, composed of NKG2D in combination with a N-terminally attached CD3-zeta. The chNKG2D receptor is generated and expressed in murine T-cells. NKG2D is a type II protein, in which the N-terminus is located intracellularly (Raulet (2003) Nat. Rev. Immunol. 3:781-790), whereas the CD3-zeta chain is type I protein with the C-terminus in the cytoplasm (Weissman, et al. (1988) Proc. Natl. Acad. Sci. USA 85:9709-9713). To generate a chimeric NKG2D-CD3-zeta fusion protein, an initiation codon ATG is placed ahead of the coding sequence for the cytoplasmic region of the CD3-zeta chain (without a stop codon TAA) followed by a wild-type NKG2D gene. Upon expression, the orientation of the CD3-zeta portion is reversed inside the cells. The extracellular...

example 3

In Vivo Administration of T Cell Receptor (TCR)-Deficient T Cells Expressing chNKG2D

[0126]In this example, the TCR-deficient T cells expressing a murine chNKG2D receptor as produced in Example 2 are administered to mice to evaluate the in vivo therapeutic potential of said T cells on certain cancers. The chimeric NKG2D-bearing T cells (106) are co-injected with RMA / Rae-1β tumor cells (105) subcutaneously to C57BL / 6 mice. Chimeric NKG2D-bearing, TCR-deficient T cell-treated mice that are tumor-free or have tumor-inhibited growth of RMA / Rae-1β tumors after 30 days reflects therapeutic anti-cancer activity in these mice.

[0127]In a second and more stringent model, transduced T cells (107) are adoptively transferred i.v. into B6 mice one day before RMA / Rae-1β s.c. tumor inoculation in the right flank. Suppression of the growth of the RMA / Rae-1β tumors (s.c.) compared with control vector-modified T cells reflects therapeutic anti-cancer activity in these mice. As for toxicity of treatment...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
compositionaaaaaaaaaa
sizeaaaaaaaaaa
compositionsaaaaaaaaaa
Login to View More

Abstract

The invention is directed to modified T cells, methods of making and using isolated, modified T cells, and methods of using these isolated, modified T cells to address diseases and disorders. In one embodiment, this invention broadly relates to TCR-deficient T cells, isolated populations thereof, and compositions comprising the same. In another embodiment of the invention, these TCR-deficient T cells are designed to express a functional non-TCR receptor. The invention also pertains to methods of making said TCR-deficient T cells, and methods of reducing or ameliorating, or preventing or treating, diseases and disorders using said TCR-deficient T cells, populations thereof, or compositions comprising the same.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS[0001]The present application is a national stage application of International Patent Application No. PCT / US2010 / 54846, filed on Oct. 29, 2010, which claims priority from U.S. Provisional Application No. 61 / 255,980, filed Oct. 29, 2009, the disclosures of which is herein incorporated by reference in its entirety.[0002]This invention was made with government support under contract number CA 130911 awarded by the National Institutes of Health. The government has certain rights in the invention.SEQUENCE LISTING[0003]This application includes a sequence listing which is being submitted via EFS-Web in a file named “76840o000103.txt” created on Aug. 23, 2012 and having a size of 31,947 bytes, which is hereby incorporated by reference in its entirety.BACKGROUND OF THE INVENTION[0004]1. Field of the Invention[0005]The invention is directed to TCR-deficient T cells, methods of making and using TCR-deficient T cells, and methods of using these TCR-defici...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(United States)
IPC IPC(8): C12N5/10C12N5/0783A61K39/00
CPCC12N5/0636A61K2039/5156C12N2501/515
Inventor SENTMAN, CHARLES L.
Owner TRUSTEES OF DARTMOUTH COLLEGE THE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com